Patents by Inventor Jeffrey John Letourneau

Jeffrey John Letourneau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azinone and diazinone V3 inhibitors for depression and stress disorders
    Patent number: 8350043
    Abstract: Substituted pyridines, pyrimidines, pyrazines, pyridinones, pyrimidinones, pyrazinones and phenylacetamides useful in treating depression, stress and other disorders are disclosed. The compounds are of the formualae: Other embodiments are also disclosed.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: January 8, 2013
    Assignee: Pharmacopeia, Inc.
    Inventors: Jeffrey John Letourneau, Koc-Kan Ho, Michael J. Ohlmeyer, Patrick Jokiel, Christopher Mark Riviello
  • N-heterocyclic inhibitors of TNF-? expression
    Patent number: 7479495
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: January 20, 2009
    Assignees: Pharmacopeia, Inc., Bristol-Myers Squibb Company
    Inventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John J. Baldwin, Alaric J. Dyckman
  • Nitrogen heterocycle biaryls for osteoporosis and other diseases
    Patent number: 7365209
    Abstract: Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: April 29, 2008
    Assignee: Pharmacopeia, Inc.
    Inventors: Jeffrey John Letourneau, Vidyahar Paradkar, Michael H. J. Ohlmeyer, Lawrence W. Dillard, John J. Baldwin, Christopher Mark Riviello, Angela Wong, Yaing Rong
  • Pyrimidine and triazine kinase inhibitors
    Patent number: 6943161
    Abstract: Compounds that selectively inhibit inappropriate kinase activities and methods for their preparation are disclosed. In one embodiment, the compounds are represented by Formula I, As selective inhibitors of inappropriate kinase activities, the compounds of the present invention are useful in the treatment of conditions associated with such activity, including, but not limited to, inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting inappropriate kinase activities and methods of treating conditions associated with such activities.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: September 13, 2005
    Assignee: Pharmacopela Drug Discovery, Inc.
    Inventors: Shawn David Erickson, James Inglese, Jeffrey John Letourneau, Christopher Mark Riviello
  • N-heterocyclic inhibitors of TNF-? expression
    Patent number: 6906067
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: June 14, 2005
    Assignees: Bristol-Myers Squibb Company, Pharmaceopeia, Inc.
    Inventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John J. Baldwin, Alaric J. Dyckman
  • Pyrimidine and triazine kinase inhibitors
    Publication number: 20030149041
    Abstract: Compounds that selectively inhibit inappropriate kinase activities and methods for their preparation are disclosed.
    Type: Application
    Filed: June 28, 2002
    Publication date: August 7, 2003
    Applicant: Pharmacopeia, Inc.
    Inventors: Shawn David Erickson, James Inglese, Jeffrey John Letourneau, Christopher Mark Riviello
  • N- heterocyclic inhibitors of TNF-alpha expression
    Publication number: 20020137747
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed.
    Type: Application
    Filed: June 26, 2001
    Publication date: September 26, 2002
    Inventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John J. Baldwin, Alaric J. Dyckman
  • N-heterocyclic inhibitors of TNF-alpha expression
    Publication number: 20020065270
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed.
    Type: Application
    Filed: December 22, 2000
    Publication date: May 30, 2002
    Inventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski